1.a. Draft Assessment.

A 2-week qualitative assessment interviewing key internal researchers. The basic check for early stage technologies.

1.b. Product viability.

A 2-month complete assessment with secondary data, interviewing key internal researchers, and a thorough analysis of publicly available information. The must-have for preparing spin-outs and obtaining seed funding.

1.c. Business Plan.

A 4-month complete assessment involving field experts, primary market research of key players and KOLs, providing a full road map and business plan. The basis for raising significant venture funding.

Biotech and medtech consultants for venture funds, industry and tech transfer offices.

1. CONSULTING

Start-up Fund Raising

Comprehensive assessment of all aspects concerning the business opportunity of your biotech or medtech technology. We partner with key experts in each field, and provide a range of services for your project analysis:

Also, if you are an established corporation and want to enter the biotech and medtech sectors, or improve your current position, we can assist you in developing the best strategy that fits your company capabilities.

If you are a start-up or want to spin-out a company in the biotech and medtech sectors, we can act as interim CEO and implement an early strategy until consolidation. Your opportunity to access experienced management in a capital efficient and flexible way to get your business off the ground.

If your product or technology has been successfully analyzed by us, we can assist you in obtaining public and private funding, connecting you with a broad investors’ network and coaching you during the process.

Services

Product or Technology Assessment

Lifescience Corporate Strategy

2. FINANCING

If you want to create a successful venture fund in the lifescience arena, we help you designing the strategy and connecting you with national and international strategic investors. We have worked successfully with tech transfer funds, accelerator funds and later-stage venture funds.

Venture Fund Strategy

3. INTERIM MANAGEMENT

Biotech and medtech consultants for venture funds, industry and tech transfer offices.

We are members of the Biospain’s Investment Jury, to help them evaluate new biomedical technologies.

We collaborate with TTS Ltd in creating and developing outstanding international tech transfer events, like the TTS Biomedtech 2013.

We are the lifescience advisors for the IESE Business Angels & Family Office Network.

Partnerships

We have an exclusivity agreement with ONE to ONE as Lifescience Industry Experts with access to all their corporate finance expertise.

Consulting expertise. More than 30 products analyzed to date in biotech and medtech, for multinationals, startups and tech transfer offices. Focus on disruptive innovation technologies.

Real world experience. Lead launch strategy for multiple new products globally. Integrate technology, IP, clinical development, CMC, regulatory, PRA & marketing.

Business Development. Closed licensing deals of up to $300mn. Out-licensing and in-licensing experience. Pipeline prioritization. Target product profiling, valuation and risk assessment.

Truly international. Working experience based in the USA, Germany, the UK and Spain, with a truly international approach. Managed multinational teams of experts.

Broad professional network. Broad national and international network of investors and professionals in the sector. Raised over €30 million in venture capital in the past.

Track Record

We act as business advisors for m+vision, the consortium between the MIT and the Madrid Region to support joint innovation in medical devices.

PDE5 inhibitor for treatment of pulmonary arterial hypertension.

Pharma/Biotech

Multiparametric microchip for detection of biofilms in implanted catheters.

Medical Devices

Dendritic cell autologous vaccines loaded with tumor antigen for cancer treatment.

Advanced Therapies

PDE5 inhibitor for treatment of benign prostatic hyperplasia.

Impedimetric sensor device for endotoxin detection.

Flat electrode arrays for cochlear implant atraumatic surgery.

Biodegradable nanofiber polymer for direct chemotherapy delivery in glioblastoma treatment .

LSCD corneal regeneration with limbal tissue cultured on polymeric scaffolds.

Biodegradable drug eluting stents with nanofiber polymers.

Wound healing nanofiber bandages with drug delivery technology.

RNA‐sequencing biomarkers for cancer diagnosis and prognosis.

DNA marker-based kit to predict rectal cancer response to neoadjuvant RCT.

Interactive real-time platform for biological soft tissue mechanical behaviour simulation.

Magnetic resonance elastography system to improve brain imaging.

Robotic computer assisted surgery for transpedicular spine fixation.

Cultured autologous melanocytes on a nanofiber scaffold for vitiligo treatment.

Estrogen receptor β for treatment of BPH.

PDE5 inhibitor for treatment of Peyronie’s disease.

ADP receptor inhibitor for treatment of acute coronary syndrome.

Biotech and medtech consultants for venture funds, industry and tech transfer offices.

Examples of technologies analyzed to date

Relevant

Unique

Protectable Achievable

Profitable

Is there a real unmet need for your tech today?

Will it stay competitive in the future?

Can it be protected from copyists? What risks & barriers may prevent success?

How profitable and cashable is it? What

WRAPUP©. Our proprietary product assessment approach

www.dynomicsbmt.com Now follow us at: